tirzepatide nejm SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants Tirzepatide for Obesity Treatment and
Description
It's good for your brain
When your appetite is suppressed by Mounjaro, every bite you take needs to count
Most policies restrict GLP-1 medications to diabetes treatment only, leaving millions of Americans to self-fund their therapy
We thank Palisades Therapeutics and Dr
Semaglutide Induces Weight Loss in Subjects With Type 2 Diabetes Regardless of Baseline BMI or Gastrointestinal Adverse Events in the SUSTAIN 1 to 5 Trials
